GSK 2033
| 中文名称 | GSK 2033 |
|---|---|
| 中文同义词 | 化合物GSK2033;GSK2033,LXR拮抗剂 |
| 英文名称 | GSK 2033 |
| 英文同义词 | GSK 2033;LXR antagonist 2033;2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide;Benzenesulfonamide, 2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]-;GSK2033 >=98% (HPLC);Liver X receptor,Inhibitor,GSK 2033,inhibit,LXR,GSK2033,GSK-2033 |
| CAS号 | 1221277-90-2 |
| 分子式 | C29H28F3NO5S2 |
| 分子量 | 591.66 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1221277-90-2.mol |
| 结构式 |  |
GSK 2033 性质
| 储存条件 | 2-8°C |
|---|---|
| 溶解度 | DMF:5.0(最大浓度 mg/mL);8.45(最大浓度 mM) DMSO:17.46(最大浓度 mg/mL);29.51(最大浓度 mM) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
pIC50: 7 (LXRα), 7.4 (LXRβ)
GSK2033 is a LXR antagonist with pIC 50 s of 7 and 7.4 for LXRα or LXRβ, respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXRα or full-length LXRβ cotransfection assays with IC 50 s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an ABCA1 driven luciferase reporter dose-dependently displaying IC 50 s of 52 nM for LXRα and 10 nM for LXRβ. GSK2033 also suppresses the expression of both of fatty acid synthase ( FASN ) and SREBP1 .
One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels. Plasma triglyceride levels are also unaffected by treatment with GSK2033.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-108688 | GSK2033 | 1 mg | 457元 | |
| 2024/04/30 | HY-108688 | 1221277-90-2 GSK2033 | 1221277-90-2 | 5mg | 1100元 |